Search peptides, terms, sources/
Growth hormone axis

Tesamorelin

Also known as: TH9507

Not licensed in the UK. Growth-hormone-releasing hormone analogue studied for visceral fat in HIV-associated lipodystrophy, in randomised trials.

UK status and evidence last reviewed .

UK status
Not licensed in the UKChecked

Evidence grade: best single recorded finding

How grading works

Best recorded finding: Strong evidence (level 4 of 4 on our scale)

This grades the evidence behind one recorded finding. It does not rate the compound.

2 findings at this grade. See all findings

These labels summarise the recorded evidence and the UK regulatory position. They are not recommendations. None of them means a product is safe to obtain or use, and none of them means a product is licensed or lawful to supply. Tesamorelin is recorded as not licensed in the UK (checked 14 August 2026).

Best study type
Human trials2 human trials

What is Tesamorelin?

Tesamorelin is a synthetic analogue of growth-hormone-releasing hormone, studied for reducing visceral abdominal fat in adults with HIV-associated lipodystrophy and not for general weight loss. It holds no UK marketing authorisation. It has been studied in five randomised controlled trials in that population, pooled in a meta-analysis.

In the US it is approved, as Egrifta, for this use. It has no EU marketing authorisation: an EU application was withdrawn after an unfavourable assessment by the EMA's CHMP.

Class
GHRH analogue
Origin
Analogue / modified
UK status
Not licensed in the UK
Best study type
Human trials
Evidence last reviewed

How does Tesamorelin work?

Tesamorelin is a stabilised version of growth-hormone-releasing hormone. It tells the pituitary gland to release the body's own growth hormone, which raises a related hormone called IGF-1. In trials in people with HIV-associated lipodystrophy this was linked to less fat around the organs, but not less fat under the skin.

The mechanism in more detail

Tesamorelin is a stabilised synthetic analogue of growth-hormone-releasing hormone (GHRH). It acts on the pituitary gland to stimulate release of the body’s own growth hormone, which in turn raises circulating IGF-1. In the pivotal human trial programme, this stimulation of the GH/IGF-1 axis was associated with a selective reduction in visceral adipose tissue (the fat surrounding internal organs), without a corresponding reduction in subcutaneous fat or change in body mass index. This is a body-composition-specific effect, not general weight loss, and the evidence base does not support extending it to weight management outside this context.

The evidence for this mechanism comes from a pivotal, multicentre, placebo-controlled trial in adults with HIV-associated abdominal fat accumulation, later confirmed and extended by a 2026 meta-analysis pooling five randomised controlled trials, which reported consistent reductions in visceral fat and hepatic fat alongside increases in lean body mass and IGF-1. Both the original trial and the meta-analysis population were specific to HIV-associated lipodystrophy; this evidence has not been shown to generalise to visceral fat or body composition in a general, non-HIV population.

The same sustained IGF-1 elevation that underlies tesamorelin’s studied effect was also the basis of a safety concern raised by European regulators when reviewing the compound for an EU marketing authorisation, discussed further in the Safety Findings and Regulatory Status sections of this page.

Classification and structure

Names
Tesamorelin; TH9507
Class
GHRH analogue
Origin
Analogue / modified
Routes used in the research
Subcutaneous injection in all cited human trials. This reflects study methodology, not a usage instruction.How the substance was given in the studies cited on this page. This describes study methods only. It is not guidance on use.

What does the research show?

Tesamorelin has 2 recorded research findings. Each shows how strong it is, the kind of study behind it, its source and its main limitation.

Findings by strength of evidence

2 findings

Counts recorded findings by grade. It does not rate the compound.

Findings by strength of evidence
PreliminaryLimitedModerateStrongNot graded
00020

HIV visceral fat trial Strong

In a multicentre, randomised, double-blind, placebo-controlled trial in adults with HIV-associated abdominal fat accumulation (26-week primary period plus 26-week safety extension), subcutaneous tesamorelin produced a significant reduction in visceral adipose tissue as measured by CT scan, with associated IGF-1 elevation and improvement in some cardiometabolic markers, and no significant change in subcutaneous fat or BMI versus placebo.

Study type
Human trial
Population
Human, HIV-infected adults with abdominal fat accumulation, multicentre, randomised double-blind placebo-controlled, 26-week primary plus 26-week extension
Source
1 Falutz et al., 2007

Limitation: Population specific to HIV-associated lipodystrophy; findings should not be generalised to visceral-fat reduction in the general non-HIV population without a separate supporting study.

2026 meta-analysis, five trials Strong

A 2026 meta-analysis of 5 randomised controlled trials of tesamorelin versus placebo in HIV-associated lipodystrophy found tesamorelin significantly reduced visceral adipose tissue (pooled mean difference -27.71 square centimetres versus placebo) and hepatic fat percentage (-4.28 percentage points), and increased lean body mass (+1.42 kg), IGF-1, and improved other body-composition and hepatic-fat outcomes, without serious adverse events or a significant effect on glucose metabolism across the pooled trials.

Study type
Human trial
Population
Human, HIV-infected adults with lipodystrophy, pooled across 5 RCTs
Source
2 Badran et al., 2026

Limitation: Pooled estimate from five randomised trials, all in people with HIV-associated lipodystrophy.

Limitations in full

Pooled estimate from five randomised trials, all in people with HIV-associated lipodystrophy. The abstract gives no certainty-of-evidence rating and no total number of participants.

What safety findings have been reported?

2 safety findings are recorded for Tesamorelin. A short list does not mean a substance is safe; it reflects what has been studied and reported.

Pooled trial adverse-event reporting

A 2026 pooled analysis of five trials reported no serious adverse events attributable to tesamorelin. The abstract gives no total number of participants, so rarer harms cannot be ruled out.

Source
2 Badran et al., 2026

EMA IGF-1 elevation concern

In its 2012 assessment of the subsequently withdrawn EU marketing-authorisation application for Egrifta, the EMA's Committee for Medicinal Products for Human Use identified elevated IGF-1 levels in many treated patients as a safety concern, noting this could theoretically increase cancer risk and worsen diabetic eye disease, and stated that no long-term safety data had been provided despite the anticipated long-term nature of treatment.

Source
3 EMA, 2012

What is Tesamorelin's UK regulatory status?

Marketing authorisation
No UK/EU marketing authorisation. An application was submitted to the EMA (relevant to UK status at the time, pre-Brexit) by Ferrer Internacional, S.A., and formally withdrawn by the applicant on 21 June 2012 after the CHMP indicated it could not conclude on a positive benefit-risk balance.
Prescription status
Not applicable in the UK, no licensed product to classify. In the US, Egrifta/Egrifta SV is prescription-only.
Medicine class
Not a licensed medicine in the UK. Licensed in the US (Egrifta/Egrifta SV, FDA-approved 10 November 2010) for a specific indication, a genuine licensed-elsewhere history.
MHRA position
No separate UK/MHRA assessment of tesamorelin was identified beyond the EMA process, which at the time of the 2012 withdrawal governed the UK as an EU member state. No post-Brexit UK-specific tesamorelin application or MHRA notice was located. Any UK supply or sale with medicinal claims would fall under the Human Medicines Regulations 2012 general framework.
Authorised use
None in the UK/EU. In the US: FDA-approved to reduce excess visceral abdominal fat in HIV-infected patients with lipodystrophy, a narrow, population-specific indication, not a general weight-loss or body-composition approval.
Other restrictions
None identified beyond the general Human Medicines Regulations 2012 framework. In sport, the WADA 2026 Prohibited List (in force from 1 January 2026) names tesamorelin under S2.2.4, growth hormone-releasing hormone analogues.

These labels summarise the recorded evidence and the UK regulatory position. They are not recommendations. None of them means a product is safe to obtain or use, and none of them means a product is licensed or lawful to supply. Tesamorelin is recorded as not licensed in the UK (checked 14 August 2026).

References

3 sources, numbered as cited above. Each has its own page with its limitations and everything that cites it.

  1. Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S (2007). Metabolic Effects of a Growth Hormone-Releasing Factor in Patients with HIV. New England Journal of MedicineHuman clinical trial, RCT · DOI 10.1056/NEJMoa072375 · Original ↗
  2. Badran AS, Helal A, Shata KS, Ayesh H (2026). Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy, A meta-analysis of randomized controlled trials. Obesity Research & Clinical PracticeMeta-analysis, RCT · DOI 10.1016/j.orcp.2026.01.002 · PMID 41545261 · Original ↗
  3. Committee for Medicinal Products for Human Use, CHMP (2012). Egrifta (tesamorelin), EPAR, Withdrawal of marketing-authorisation application. European Medicines Agency (EMA) · Original ↗

Questions about Tesamorelin

What is Tesamorelin?

Tesamorelin is a synthetic analogue of growth-hormone-releasing hormone, studied for reducing visceral abdominal fat in adults with HIV-associated lipodystrophy and not for general weight loss. It holds no UK marketing authorisation. It has been studied in five randomised controlled trials in that population, pooled in a meta-analysis. Read what it is.

Is Tesamorelin licensed in the UK?

PeptGuru records Tesamorelin's UK status as: Not licensed in the UK. No UK/EU marketing authorisation. UK status checked 14 August 2026. This is a record of regulation, not a recommendation. Read the UK status.

What does the research on Tesamorelin show?

PeptGuru records 2 research findings for Tesamorelin: 2 from human trials. Each finding has its own evidence grade, source and main limitation. Read the research findings.

What safety findings have been reported for Tesamorelin?

2 safety findings are recorded, including: pooled trial adverse-event reporting; EMA IGF-1 elevation concern. Each is cited to its source. A short list does not mean a substance is safe. Read the safety findings.

Where are the sources for Tesamorelin?

All 3 sources are listed in the references, each with a link to the original study or regulator document and its own source page on PeptGuru. See the references.

Review record and change log

Last reviewed
Evidence last reviewed
UK status checked
Reviewed by
PeptGuru editorial team
  • Regulatory update · WADA 2026 listing added (S2.2.4).

How findings are graded: the grading method. All changes.

  • AOD-9604hGH Fragment 176-191

    Growth hormone fragment studied for weight management. Not licensed in the UK; its largest human trial showed no significant weight-loss benefit.

    Growth hormone axisHuman trialsEvidence reviewed
    ModerateNot licensed in the UK
  • CJC-1295CJC-1295 with DAC

    Long-acting growth-hormone-releasing hormone analogue studied for hormone levels in healthy adults. Not licensed in the UK; human evidence is small, short trials.

    Growth hormone axisHuman trialsEvidence reviewed
    LimitedNot licensed in the UK
  • GHRP-2Pralmorelin

    Synthetic hexapeptide that triggers growth hormone release. Not licensed in the UK; Japan licenses it only as a diagnostic test. No trial shows a health benefit.

    Growth hormone axisHuman trialsEvidence reviewed
    LimitedNot licensed in the UK
  • GHRP-6Growth hormone-releasing…

    Synthetic hexapeptide that triggers growth hormone release. Not licensed in the UK. Human studies are short hormone-response and diagnostic work; no trial shows a health benefit.

    Growth hormone axisHuman trialsEvidence reviewed
    LimitedNot licensed in the UK

Compare Tesamorelin with AOD-9604

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.